Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spark Sets Sights On Bringing First Gene Therapy To Market In 2018

Executive Summary

A BLA for a potential gene therapy to correct vision loss due to certain inherited retinal disease has been accepted by FDA with a Jan. 12 PDUFA date. The proposed trade name is Luxturna.

Advertisement

Related Content

Horama's Gene Therapies For Retinal Diseases: Fast Followers?
Keeping Track Of Novel Agents: US FDA Approves Nerlynx And Vosevi, Turns Down Evenity; Macrilen Returns
Gene Therapy Reimbursement: Is Blindness A Bad First Test?
White Flag Raised: UniQure Gives Up On Glybera, But Not Gene Therapies
Spark Restores Vision In Phase III; CEO Hopes To Lead Gene Therapy Field
Spark ignites investors; one of year's first five biotech IPOs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel